Skip to main content

Table 1 Summary of mutations targeting cyclin D1 phosphorylation or ligase function

From: Speeding through cell cycle roadblocks: Nuclear cyclin D1-dependent kinase and neoplastic transformation

Target

Mutation

Consequence

Tumor Type

Reference

Cyclin D1

T286R

Constitutively Nuclear

Esophageal

[18]

Cyclin D1

Δ266–295

Constitutively Nuclear

Esophageal

[18]

Cyclin D1

P287A

Constitutively Nuclear

Tumor-derived esophageal carcinoma cell lines TE3, TE7, and TE12

[18]

Cyclin D1

P287S/T

Constitutively Nuclear

Endometrial

[17]

Cyclin D1

Δ289–292

Constitutively Nuclear

Endometrial

[17]

αB crystallin

Chromosome 11 deletion

Impaired ligase activity

Tumor-derived breast cancer cell lines (MCF-7, MDA-MB 231)

[14]

Fbx4

S8R

Impaired ligase activity

Esophageal

[26]

Fbx4

S12L

Disrupts phosphorylation

Esophageal

[26]

Fbx4

P13S

Disrupts phosphorylation

Esophageal

[26]

Fbx4

L23Q

Dimerization-deficient

Esophageal

[26]

Fbx4

P76T

Impaired Skp1 binding

Esophageal

[26]

  1. Mutations disrupting GSK3β-dependent cyclin D1 phosphorylation and nuclear export include mutation of Thr-286, Pro-287, and deletion of residues corresponding to the CRM1 binding site. Mutations targeting the SCFFbx4-αB crystallin E3 ubiquitin ligase result in impaired ligase activity and subsequent cyclin D1/CDK4 accumulation in the nucleus.